H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on PDS Biotechnology today and set a price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising developments in PDS Biotechnology’s pipeline. The company has recently reported the start of the Phase 3 VERSATILE-003 study, which is progressing as planned, indicating strong potential for future success. Additionally, the Phase 2 PDS01ADC study for colorectal cancer has met the criteria for expansion into Stage 2, following encouraging results in Stage 1, further supporting the company’s innovative approach.
Moreover, updated results from the VERSATILE-002 study were presented at ASCO ’25, enhancing the clinical profile of Versamune HPV. The company is also expected to publish a full data set from VERSATILE-002 in late 2025 or early 2026, which could provide further validation of their technology. These advancements, coupled with a solid financial position, underscore the potential for significant growth and value generation, justifying the Buy rating.